The global

Non-Invasive Blood Glucose Monitoring Systems Market

is valued at

USD 33.9 Million in 2023

and is projected to reach a value of

USD 284.43 Million by 2032

at a CAGR (Compound Annual Growth Rate) of

21.3%

between 2024 and 2032. The Market is driven by increasing demand for user-friendly & painless monitoring, and AI integration for personalized diabetes management.

Key Highlights

• In 2023, North America dominated the market with 53.20% market share
• By Technology, the Spectroscopy segment is dominated the market in 2023
• By Distribution Channel, the Retail Sales segment is dominated the market in 2023
• Based on modality, the Wearable segment is dominated the market with 56.50% market share
• Based on End user, the Homecare segment is dominated the market in 2023

{{bar_graph}}

Technology Overview

The Technology Segment is divided into Spectroscopy, Electromagnetic, microwave, ultrasonic, thermal, and Others. The Spectroscopy held the dominant share in 2023.

The need for spectroscopy technology is increasing as the number of diabetes cases and the complications associated with it will lead to the growth of the market. The significant impact of this diseases on the both families and individuals due to which the need for this technology is expected to grow in the coming years period as the non-invasive procedures are painless and quick monitoring solutions. As these technologies continue to evolve, the availability of cost-effective options will further boost market expansion during the forecast period.

Modality Overview

The Modality segment is divided into wearable and non-wearable. The wearable held the dominant share in 2023, accounting for significant market share of 56.50%.

Requirement of painless, needle-free, and continuous glucose monitoring wearable sensors to enhance the quality of life of diabetic patients is a major factor driving the segment. AerBetic producers a non-invasive blood glucose monitoring that continuously provides blood sugar levels. It also comes with an application that allows a user to set up alerts in order to communicate to a network of health care providers. For instance, in June 2024, Abbott announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbotts world-leading FreeStyle Libre® continuous glucose monitoring technology, now used by about 6 million people globally. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

Regional Overview

In 2023, the North America captured 53.20% of the revenue share.

North America

Non-Invasive Blood Glucose Monitoring Systems market is driven by high prevalence of diseases and well-established health care infrastructure that enables proper diagnosis are attributed to the North America largest share. According to the American Diabetes Association, in 2018, 34.2 million people in the U.S., or 10.5% of the population, had diabetes. Moreover, 1.6 million people have type 1 diabetes, including about 187,000 children and adolescents.

The

US

held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by rising prevalence of diabetes and increasing demand for painless monitoring solutions. The growing number of diabetes cases is pushing consumers to seek alternatives to traditional finger-prick methods, as non-invasive devices provide a pain-free option that enhances compliance.

In

Europe

, Non-Invasive Blood Glucose Monitoring Systems market is experiencing notable growth, driven by include significant technological advancements, with innovations in sensor technologies such as near-infrared spectroscopy and bioimpedance analysis, enabling accurate and painless glucose monitoring. With both established medical device manufacturers and innovative startups competing in this space, the market is expected to expand significantly as these devices become more accessible and affordable for patients across Europe.

Key Trends

• 
  

  Technological Advancements

  
  

  : Innovations in sensor technologies, such as near-infrared spectroscopy and bioimpedance analysis, are enhancing the accuracy and reliability of non-invasive monitoring

• 
  

  Integration with Digital Health Solutions

  
  

  : Many non-invasive devices are being integrated with mobile apps and digital health platforms for enhanced data tracking and management

• 
  

  Competitive Landscape

  
  

  : A mix of established medical device manufacturers and innovative startups is intensifying competition in the market, resulting in more diverse product offerings

{{dialog}}

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool:

Vantage Point

Market Dynamics

Rising Prevalence of Diabetes

The growing prevalence of diabetes among populations in both developed and emerging countries is leading to a large patient pool globally requiring blood monitoring, which is further resulting in increasing demand for these devices among the patient population. Market driven by including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of blood glucose monitoring systems globally.

High Cost Associated with CGM Systems

The initial purchase price of CGM devices can be substantial, ranging from several hundred to over a thousand dollars, and sensors, which typically need replacement every 7 to 14 days, add significant ongoing expenses. Insurance coverage for CGM systems varies widely, with some plans providing limited coverage or imposing strict approval criteria, leaving patients to shoulder the financial burden. Additionally, proper use of CGM systems often requires training for both patients and healthcare providers, leading to extra costs for consultations and follow-up appointments.

Competitive Landscape

The Non-Invasive Blood Glucose Monitoring Systems market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Abbott Laboratories, Medtronic plc, Dexcom Inc, Ascensia Diabetes Care, Sanofi Novo Nordisk, Insulet corporation, Glysens Incorporated, F.hoffman-La Roche Ltd., Taiwan Biophotonic Corporation. Companies are also forming strategic partnerships with healthcare providers and technology firms to enhance their offerings and navigate regulatory approvals. With the global rise in diabetes cases, companies are expanding geographically to capture new markets, especially by securing key regulatory approvals.

Recent Market Developments

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronics Insulin Delivery Devices

• In August 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbotts most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronics automated insulin delivery (AID) and smart insulin pen systems

The global Non-Invasive Blood Glucose Monitoring Systems market can be categorized as Technology, End User, Modality, Distribution Channel and Region.